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Title of the manuscript: A narrative review of nutrition assessment in Crohn’s disease using 1 
anthropometric, biochemical and dietary indices. 2 
 3 
Research Snapshot   4 
Research question: What is the existing evidence to inform a comprehensive nutrition 5 
assessment of patients with Crohn’s disease?   6 
Key findings: There were heterogeneous findings on nutrition status in Crohn’s disease. 7 
Significant deficits in fat mass, fat-free mass and muscle strength were observed. Lower serum 8 
micronutrient levels, micronutrient intakes and fruit and vegetable intakes were reported in 9 
patients with Crohn’s disease compared with healthy controls. The findings from this narrative 10 
review have informed the development of a practical clinical guide for comprehensive nutrition 11 
assessment of patients with Crohn’s disease. 12 
4 
 
Abstract  13 
Malnutrition is common in patients with Crohn’s disease and negatively impacts immunity and 14 
quality of life. The optimal tools for nutrition assessment in patients with Crohn’s disease are 15 
not clearly defined and lead to variations in practice. This review aims to appraise the existing 16 
evidence for nutrition assessment of patients with Crohn’s disease compared with healthy 17 
controls and provide a comprehensive guide with relevant measures applicable to clinical 18 
practice. A literature search using Medline, Embase and Scopus from inception to 1st October 19 
2018 was conducted. Forty-one papers which assessed body composition, muscle strength, 20 
micronutrient status and/or dietary intake in adults with Crohn’s disease compared with an age 21 
and sex-matched healthy population were included. There were heterogeneous findings on 22 
nutrition status in Crohn’s disease compared with healthy controls.  Only one paper reported a 23 
clinically significant difference for BMI; however significant deficits in fat mass, fat-free mass 24 
and muscle strength were observed in Crohn’s disease compared with healthy controls, with 25 
more pronounced differences with increasing disease activity and length of diagnosis. Most 26 
research reported significantly lower serum micronutrients in Crohn’s disease compared with 27 
healthy controls. Half of studies measuring micronutrient intake reported lower intakes in 28 
Crohn’s disease compared with healthy controls. Fruit and vegetable intake was also lower in 29 
Crohn’s disease. Difficulties characterising the type and prevalence of malnutrition exist due 30 
to the heterogeneous nature of Crohn’s disease and warrants continued investigation. This 31 
review advocates that a nutrition assessment should include more parameters than weight and 32 
body mass index.   33 
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Introduction  34 
Malnutrition is a significant issue in Crohn’s disease with an estimated prevalence between 20-35 
85%, depending on the criteria used.1 It is associated with increased susceptibility to infections, 36 
gastrointestinal barrier dysfunction, post-operative complications and reduced quality of life.2-37 
4 38 
Reasons for malnutrition in Crohn’s disease are multifactorial. More than 80% of people with 39 
Crohn’s disease experience problems with food5 and 72% alter their diet as a result;6 often 40 
leading to insufficient nutrient intakes.7 Active disease is associated with reduced appetite, low 41 
mood and abdominal pain1 and mucosal inflammation causes malabsorption due to damaged 42 
intestinal microvilli8 and increased diarrhea, leading to a loss of electrolytes and fluids.9 43 
Systemic inflammation elevates nutrient requirements due to catabolism causing weight loss.1 44 
The inflammatory response produces cell-damaging free radicals; micronutrients act as 45 
antioxidants to reduce damage therefore, prolonged inflammation eliminates micronutrients 46 
via excessive utilization.10 Pharmacological side effects also contribute to malnutrition. 47 
Corticosteroids increase adiposity and are associated with reduced bone mineral density.11  48 
Micronutrient deficiencies in Crohn’s disease are a further healthcare burden. Inflammation 49 
and suboptimal vitamin D levels are associated with impaired bone mineral density, making 50 
osteoporosis common in Crohn’s disease.12 Dietary deficits in zinc reduce muscle mass and 51 
strength13 which has deleterious consequences on functional ability and activities of daily 52 
living.14 Suboptimal circulating concentrations of folic acid, vitamin B12, vitamin C and 53 
selenium in Crohn’s disease have also been reported.15, 16 The risk of malnutrition persists 54 
during the remission phase of the disease; whilst 86% of patients with active disease avoid 55 
certain foods during flare ups, 77% of patients continue to avoid certain foods during remission 56 
to prevent disease relapse.7 57 
 58 
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In clinical practice, nutrition assessment in patients with Crohn’s disease remains challenging 59 
and most frequently is measured using weight and body mass index (BMI).17 Weight and BMI 60 
are inadequate measures of malnutrition in Crohn’s disease as systemic inflammation alters 61 
body composition meaning BMI may mask deficits in lean mass due to increased fat mass.18 62 
However, there are no guidelines on what components should be included in a comprehensive 63 
nutrition assessment of patients with Crohn’s disease.  64 
 65 
Accurate quantification of nutrition status in Crohn’s disease is essential to enable diet and 66 
nutritional therapy to be targeted to address specific deficits. However, in a study on nutrition 67 
assessment in patients with Crohn’s disease, body composition was measured in only 3%, 68 
hand-grip strength in only 4% and dietary micronutrient intake in 16% of patients, suggesting 69 
that current assessments are limited.17  70 
 71 
This narrative review comprehensively appraises the existing evidence for nutrition assessment 72 
of patients with Crohn’s disease, in comparison to a healthy population. It aims to provide a 73 
comprehensive guide with relevant measures applicable to clinical practice. 74 
 75 
Methods 76 
Search strategy and study selection  77 
The PICOT framework (population, intervention, comparison, outcomes and type of study) 19 78 
was used to inform the criteria needed to answer the research question “what evidence exists 79 
on the nutrition status of patients with Crohn’s disease and how can this evidence inform 80 
nutrition assessment in clinical practice?”. The search strategy included studies of patients 81 
with Crohn’s disease aged 18 to 64 years using validated assessment methods available in 82 
clinical practice to establish nutrition status compared with a healthy age and sex matched 83 
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control (HC) group sampled from the same population as those with Crohn’s disease. Studies 84 
which reported nutrition status outcomes including body composition, muscle strength and 85 
function, micronutrient status and/or dietary intake were included if they were in the English 86 
language and primary research or systematic reviews.  87 
Limiting the search in this way allowed the literature review to establish a ‘typical’ nutrition 88 
status in healthy people without Crohn’s disease and facilitated the comparative quantification 89 
of nutrition status in Crohn’s disease. Whilst anthropometric reference ranges for the healthy 90 
population have been developed, these vary depending on assessment methods used.20 91 
Recruiting a HC group ensures comparisons are made using identical methods to those used 92 
with Crohn’s disease patients. Three databases were searched (Medline®, Embase® and 93 
Scopus®) on 1st October 2018. Multiple search terms were combined with the Boolean 94 
functions ‘and’ and ‘or’ to focus the search.21 The medical library subject heading terms or 95 
keywords included were [Crohn’s disease OR inflammatory bowel disease] AND [nutrition* 96 
assessment, body composition, body fat, fat mass, anthropometry, lean body weight, 97 
malnutrition, protein energy malnutrition, muscle strength, hand grip, grip strength, trace 98 
element, nutrition* status, nutrition* deficiency, vitamin deficiency, mineral deficiency, 99 
dietary intake, diet OR micronutrient]. Filters (English, human and adult aged 18 – 64 years) 100 
were applied to target the search results. 101 
 102 
Following removal of duplicates, the titles, and where applicable abstracts, were screened for 103 
relevance. Abstracts of relevant titles were reviewed and if a HC group was described the full 104 
text was examined against the inclusion and exclusion criteria.  105 
 106 
Data extraction and synthesis 107 
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Eligible studies for data synthesis were critically appraised using the ‘assessing methodological 108 
quality’ question checklist in Greenhalgh (2006) and the ‘Critically appraising papers’ chapter 109 
process in Hickson (2008) to assess quality of individual studies.22, 23 Data were summarized 110 
in a data extraction spreadsheet according to anthropometric, biochemical and dietary 111 
assessment techniques (as per the Nutrition Care Process structure). The Nutrition Care Process 112 
was developed by the Academy of Nutrition and Dietetics and is used by nutrition professionals 113 
to ensure systematic, evidence-based nutrition care.24 Outcome data was only extracted if 114 
available and clinically relevant. Anthropometric outcomes included: assessment of body 115 
composition using direct anthropometry, bioelectrical impedance analysis (BIA), dual energy 116 
X-ray absorptiometry (DEXA), computed tomography (CT) or magnetic resonance imaging 117 
(MRI) and muscle strength or function measurements. Biochemical outcomes included: plasma 118 
or serum markers of nutrition status including folic acid, vitamin B12, vitamin C, vitamin D, 119 
zinc, copper and selenium. Iron status and albumin were not collected as these are acute phase 120 
reactants and results are difficult to compare with a HC population. Dietary intake outcomes 121 
included: macronutrient and micronutrient intake, food group intake or exclusions of specific 122 
food groups. Where possible the anthropometric, biochemical and dietary assessment methods 123 
and results were compared and critiqued across studies. 124 
 125 
Discussion 126 
To our knowledge, this is the first review appraising the evidence for methods of nutrition 127 
assessment in patients with Crohn’s disease relevant to clinical practice. There were 41 eligible 128 
papers (Figure 1) including 2370 Crohn’s disease patients and 4450 healthy controls. All 129 
studies were cross-sectional in design. The Crohn’s disease cohorts included patients with 130 
active disease and/or disease in remission. Most studies included males and females with the 131 
exception of two studies which reported body composition data of only males25 or only 132 
9 
 
females.26 Nevertheless, compared with HC, there were significant differences in body 133 
composition and dietary intake as well as deficits in muscle strength and serum micronutrients. 134 
The findings follow the Nutrition Care Process (anthropometric, biochemical and dietary 135 
assessment structure) and include recommendations for clinical practice (Figure 2). 136 
 137 
Anthropometric Outcomes 138 
Clinically relevant, and commonly available, anthropometric assessments methods were 139 
reviewed.  140 
 141 
Body Mass Index 142 
In the majority of studies (n=18) BMI was not significantly different between patients with 143 
Crohn’s disease and HC (Table 1)11, 13, 15, 16, 25, 27-39 but in eight of these studies, significant 144 
differences in body composition were observed.11, 15, 16, 25, 29, 30, 34, 39 Where significant 145 
differences in BMI existed (n=12), it was always lower in patients with Crohn’s disease 146 
compared with HC.40-51 However, studies rarely assessed clinically significant differences in 147 
BMI, as BMI tended to be reported as a mean rather than as the proportion of patients that had 148 
a clinically underweight BMI (less than 18.5kg/m2).52  Only one study assessed this, and the 149 
prevalence of underweight BMI was 21% in Crohn’s disease and 2-4% in HC.38 150 
 151 
Dual Energy X-ray Absorptiometry (DEXA)  152 
Seven studies used DEXA to determine body composition (Table 1).11, 28-30, 34, 43, 48 DEXA 153 
studies most frequently found no difference in fat mass (FM) between patients with Crohn’s 154 
disease and HC28, 29, 34, 43, 48 but a trend of fat-free mass (FFM) depletion in patients with 155 
Crohn’s disease.11, 34, 48 Superior FFM was observed in patients with newly diagnosed Crohn’s 156 
disease compared with HC.28, 29 The only study to include patients with longstanding Crohn’s 157 
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disease (>5 years) found they had significantly lower FFM compared with HC.30 These 158 
findings suggest that lean mass depletion in Crohn’s disease occurs over time. One study 159 
recruited patients with active Crohn’s disease and showed that BMI was significantly lower in 160 
the active disease group as was FFM and FM was non-significantly different when compared 161 
with HC.48 DEXA scans have ethical and practical limitations. Small amounts of radiation are 162 
absorbed by bone and tissue and increasing exposure to radiation is linked to an increased 163 
cancer risk.53 Additionally, whole body DEXAs are conducted by specialist radiographers54 164 
which presents a practical barrier for routine clinical use.  165 
 166 
Bioelectrical Impedance (BIA)  167 
Eleven studies used BIA to determine body composition (Table 1).13, 15, 16, 25, 39, 41, 42, 44-47 In 168 
contrast to DEXA, the majority of BIA studies observed a lower FM in patients with Crohn’s 169 
disease compared with HC15, 39, 45-47, 55 but, as Table 1 demonstrates, the results were not 170 
consistent.13, 16, 25 For FFM, there were no consistent differences between groups.  171 
 A study from India in patients with active Crohn’s disease detected significant deficits in FM 172 
and FFM.45 However, it lacks external validity to non-Indian populations as recent data 173 
demonstrates significant ethnic disparities in body composition, especially in South Asians.56 174 
Another study in patients with active Crohn’s disease reported lower FM compared with HC. 175 
39 Thus, there are body composition deficits in active Crohn’ disease, highlighting the 176 
importance of considering disease activity in the clinical assessment section of the Nutrition 177 
Care Process.   178 
 179 
CT and MRI  180 
Three studies used medical imaging techniques to further explore body composition.25, 26, 37 181 
One study undertook umbilicus CT scanning to determine body fat distribution alongside 182 
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BIA.25 They found intraabdominal fat was significantly higher in Crohn’s disease versus HC.  183 
Furthermore, using MRI, visceral adipose tissue was significantly higher in patients with CD 184 
in remission compared with HC.26 In another study, CT scans were used to characterise muscle 185 
size.37 Quadricep muscle cross-sectional area was 14% lower in Crohn’s disease compared 186 
with HC however, this was not statistically significant.  187 
 188 
Muscle Strength and Function  189 
Eight studies  assessed muscle strength and function.13, 16, 28, 29, 36, 39, 44, 57 Limited studies have 190 
reported on the potential effect of disease duration on muscle strength or function.16, 36 In 191 
patients with newly diagnosed Crohn’s disease, muscle strength is similar to HC;29 whereas at 192 
least five years after diagnosis, the literature suggests a reduction in muscle strength and 193 
increased muscle fatigue in active disease or disease in remission.16, 28, 36, 57 However, disease 194 
activity may impact upon muscle strength.39, 44  195 
 196 
There are no reports of change in muscle strength over time in patients with Crohn’s disease 197 
compared with HC. It is unknown if reduced muscle strength during active disease is a 198 
temporary reduction in strength associated with a disease flare and if, or how quickly, muscle 199 
strength improves once the disease is in remission.  One study found no difference in hand grip 200 
strength but reduced muscle endurance between patients with Crohn’s disease in remission for 201 
at least three months compared with HC.13 Longitudinal research on muscle strength during 202 
periods of active disease and disease remission would provide further understanding on the 203 
impact of acute and chronic inflammation on muscle strength and function. Muscle wasting 204 
and weakness in Crohn’s disease results in fatigue and reduced quality of life;13 both of which 205 
are prevalent in people living with Crohn’s disease.58, 59 206 
 207 
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Direct Anthropometry 208 
Five studies report the use of direct anthropometry in their methods,16, 28, 40, 46, 47 however, three  209 
do not report their data.16, 46, 47 The authors cite strong correlations between their direct 210 
anthropometry results and BIA/DEXA as a justification for presenting only the results of the 211 
latter. However, critics may argue this preferential inclusion of BIA/DEXA results at the 212 
expense of omitting anthropometric data represents reporting bias.60 Direct anthropometry is 213 
the most frequently used body composition assessment method in clinical practice because of 214 
its low cost and feasibility.61 Therefore, there is a missed opportunity for this unreported 215 
anthropometric data to be available to clinicians. 216 
 217 
One study calculated body FM percentage using composite measures of skin fold thickness 218 
from the bicep, tricep, subscapular and suprailiac.28 FM percentage and muscle mass did not 219 
differ significantly between patients with Crohn’s disease and HC. This finding that the body 220 
composition of Crohn’s disease patients is not inferior to HC is surprising; especially 221 
considering 47% of the group had active disease (CDAI >150). In another study, lower tricep 222 
skin fold thickness was reported in males with Crohn’s disease compared with HC males, 223 
whilst there was no difference between females, suggesting there may be sex differences.40  224 
 225 
Summary for Anthropometric Outcomes 226 
The majority of studies found no significant difference in BMI between Crohn’s disease and 227 
HC groups11, 13, 15-17, 25, 27-34, 36, 37, 39, 41 confirming that using BMI alone provide limited data for 228 
an optimal nutrition assessment. Only 14 studies examined FFM and FM, half of which suggest 229 
that FFM is decreased in Crohn’s disease11, 16, 29, 30, 34, 45, 48 and two studies suggests that intra-230 
abdominal FM is greater in Crohn’s disease than HC.25, 26 A reduction in muscle endurance in 231 
Crohn’s disease, and reduced muscle strength during active or longstanding Crohn’s disease 232 
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has been reported.13, 16, 28, 36, 39, 44, 57 BIA is a more feasible and less invasive measure of body 233 
composition than CT or DEXA scans.61  However, the routine use of BIA in clinical practice 234 
may be time intensive and financially challenging; thus, mid-arm anthropometry and HGS are 235 
measures that can be readily and cheaply assimilated into clinical practice61 (Figure 2). As body 236 
composition fluctuates over the disease course, anthropometric assessments should be repeated 237 
to monitor change. 238 
 239 
Biochemical Outcomes 240 
Comprehensive plasma micronutrient studies are arguably lacking, with most papers only 241 
quantifying two or three micronutrients.50, 62-67 Geerling et al are the only research group to 242 
measure an extensive range of micronutrients.28, 29 A major limitation of the 18 micronutrient 243 
studies (Table 2 and Table 3)27-29, 31-33, 49-51, 57, 62-70 is that only two15, 16 report deficiency 244 
prevalence for micronutrients other than vitamin D. In clinical practice, patients are not treated 245 
for low micronutrient levels unless they are deficient,71 thus it would be more clinically relevant 246 
to report the prevalence of micronutrient deficiency rather than mean micronutrient levels. 247 
 248 
Disease activity was reported in all but three of the studies.63, 65, 66 The remaining studies 249 
reported micronutrient concentrations in either patients with Crohn’s disease in remission28, 62 250 
or in a heterogenous patient group.29, 50, 62, 63, 65-67 There were no studies comparing 251 
micronutrient differences between active and remission Crohn’s disease, although the validity 252 
of measuring micronutrients in active disease is questionable. In clinical practice, and in the 253 
included studies, micronutrients are quantified in the plasma fraction of blood. However, 254 
inflammatory responses in active Crohn’s disease have been found to decrease plasma 255 
micronutrient concentrations by decreasing albumin, independent of their actual body stores.72 256 
Micronutrients on circulating erythrocytes provide a more accurate marker of micronutrient 257 
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stores, particularly for zinc, copper, selenium, vitamin B2 and vitamin B6, but this analysis is 258 
not available in routine clinical practice. Indeed, the transport protein for copper increases in 259 
the acute phase response, which may explain one study’s finding of significantly higher serum 260 
levels of copper in patients with Crohn’s disease compared with HC.65  261 
 262 
Summary for Biochemical Outcomes 263 
The majority of studies reported lower mean levels of circulating micronutrients in patients 264 
with Crohn’s disease compared with HC; including folic acid, vitamin B12, vitamin C, vitamin 265 
D, zinc, and selenium.28, 29, 50, 62, 63, 65, 66 The majority of studies reported higher prevalence of 266 
vitamin D deficiency in patients with Crohn’s disease compared with HC.28, 31, 33, 49, 51, 69 Whilst 267 
the review findings do not support the routine measurement of vitamin B6 and thiamine in all 268 
Crohn’s disease patients, consideration must be given to their jejunal absorption site. For 269 
patients with small bowel disease or previous resection, it is common practice to measure 270 
micronutrients absorbed at the jejunum every 3-6 months.73 See Figure 2 for key micronutrients 271 
that should be measured in Crohn’s disease in clinical practice, and their accuracy in reflecting 272 
body stores during the acute phase response.  273 
 274 
Dietary Assessment Outcomes 275 
Eleven studies assessed dietary intake and the main findings are summarised in Table 4.15, 16, 276 
25, 27-29, 38, 40, 45, 46, 62 Energy intake was similar between patients with Crohn’s disease and HC 277 
in eight studies15-17, 25, 27-29, 62 and lower in the other three studies,40, 45, 46 especially in patients 278 
with a lower BMI.40, 45 Although nine studies15, 25, 28, 29, 38, 40, 45, 46, 62 measured protein intake, 279 
seven of these found no significant differences in intakes between groups (Table 4).15, 28, 29, 38, 280 
40, 46, 62 Patients with Crohn’s disease tended to consume a high percentage of total energy from 281 
carbohydrate compared with HC,29, 40, 45 similar sugar intake28, 40 and similar fat intake,15, 17, 25, 282 
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28, 62 with the exception of two studies where the percentage of total energy from fat was lower 283 
in patients with Crohn’s disease.45, 46  284 
 285 
Six studies measured dietary micronutrient intake; three found no difference between patients 286 
with Crohn’s disease and HCs27-29 whereas another three found lower intakes of beta-carotene, 287 
vitamin B1, vitamin B6, vitamin C, vitamin D, vitamin E, vitamin K, calcium and zinc.15, 17, 40 288 
 289 
In two studies, patients with Crohn’s disease consumed less fruit and vegetables compared with 290 
HC16, 40 and this lower intake was associated with a low vitamin C intake. Another study 291 
showed that fiber intake was significantly lower in patients with Crohn’s disease compared 292 
with HC, and none of the Crohn’s disease group met the recommended fiber intake.28 293 
Interestingly, no studies assessed whether low fruit and vegetable intake in Crohn’s disease 294 
was associated with a reduction in fiber intake.  295 
 296 
Summary for Dietary Assessment Outcomes 297 
Macronutrient intake is similar between patients with Crohn’s disease and HC, however 298 
micronutrient and fiber intakes may be impaired; whether this is due to temporary food 299 
exclusions during active disease or longer-term food exclusion is not described in the literature. 300 
Dietary intake assessment is an essential component of nutrition assessment (Figure 2). The 301 
most appropriate dietary assessment is dependent on the patient care setting. If using a diet 302 
history of usual intake, it is important to ask about food exclusion behaviors and frequency of 303 
consumption of key food groups high in micronutrients and fiber to identify the potential for 304 
inadequate nutrient intake.  305 
 306 
Limitations of studies in this area.   307 
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The heterogeneity may be due to underpowered studies, small sample sizes and inadequate 308 
characterization of disease activity. Only three studies report a sample size calculation.36, 38, 49 309 
Furthermore, results of no significance may be attributed to type II error secondary to small 310 
sample groups.74 For example, one study used small Crohn’s disease groups of n=5 and n=7. 311 
41 Limited standardization for disease activity is evident; in 22 studies, the Crohn’s disease 312 
group comprised patients with active disease or disease in remission. Sixteen studies analysed 313 
the Crohn’s disease group in remission only,13, 15-17, 27, 28, 31, 32, 34, 40, 43, 45-47, 57, 62 with merely 314 
three studies recruiting a distinct active Crohn’s disease group.44, 45, 48 Nutrition status in active 315 
disease is more likely to be compromised compared with disease in remission due to increased 316 
malabsorption, inflammation and oxidative stress.75 Evidently, there is a paucity of literature 317 
exploring this. Of the studies that did specifically assess active Crohn’s disease, significant 318 
deficits were seen in body composition and dietary intake, warranting more investigation into 319 
the effect of disease activity. The majority of evidence is for patients in remission, thus 320 
potentially underestimating the prevalence of malnutrition in Crohn’s disease.  321 
 322 
Efforts were made to counteract the heterogeneity of the included studies. Only studies 323 
comparing Crohn’s disease with an age and sex matched HC were included. Limiting the search 324 
in this way allowed the literature review to establish a ‘typical’ nutrition status in healthy 325 
people without Crohn’s disease and facilitated the comparative quantification of nutrition status 326 
in Crohn’s disease. The inclusion of a HC group ensures comparisons are drawn using identical 327 
methods to those used in patients with Crohn’s disease. Additionally, the use of a local 328 
population increases internal validity of the results. For example, vitamin D status is highly 329 
dependent on latitude76 so recruiting HC from the local population reduces this confounder. 330 
 331 
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Implications for Clinical Practice  332 
This review has important implications for clinical practice. The UK IBD Standards (2013),77 333 
Gastroenterological Society of Australia Clinical guidelines (2018)78 and European Society for 334 
Clinical Nutrition and Metabolism guidelines (ESPEN, 2017)79 all state that all IBD patients 335 
should have access to a dietitian; however, there is a paucity of evidence-based 336 
recommendations on how clinicians should assess malnutrition in Crohn’s disease. Guidelines 337 
from the British Society of Gastroenterology (2004)80 recommend weighing IBD patients as a 338 
minimum requirement for a nutrition assessment and the American Gastroenterological 339 
Association management of Crohn’s disease guidelines (2018) recommend routine laboratory 340 
testing to screen for malnutrition.81 The British Dietetic Association guidelines (2014) on 341 
Crohn’s disease do not contain advice on nutrition assessment, but state this should be included 342 
as a priority in future guidelines.80, 82 Even the most recent ESPEN guidelines (2017)79 do not 343 
advise specific components that should be included in a nutrition assessment. The absence of 344 
recommended measures that should be included in a nutrition assessment have led to variations 345 
in practice.17 The creation of an evidence-based nutrition assessment tool (Figure 2), based on 346 
the findings of this narrative review, provides clinicians with recommendations which can be 347 
assimilated into the Nutrition Care Process. 348 
 349 
This review highlights that alternative methods can detect differences in nutrition status where 350 
BMI cannot. If using BMI alone, malnutrition does not appear to be an issue in Crohn’s disease. 351 
However, deficits were identified in body composition, muscle strength and serum 352 
micronutrients in Crohn’s disease compared with HC. This is of concern as a survey of UK 353 
dietitians found the most frequently used methods for nutrition assessment in Crohn’s disease 354 
were weight (98%) and BMI (89%). Only 3% of patients had their body composition measured 355 
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and 16% had their micronutrient intake quantified as part of their nutrition assessment.17 Thus, 356 
based on current practice, there is a risk malnutrition in Crohn’s disease remains undetected.  357 
 358 
The findings from this review challenge the traditionally held view that malnutrition in Crohn’s 359 
disease always presents as underweight with dietary protein-energy deficits.83 Insignificant 360 
differences in protein and energy consumption was commonly reported15, 17, 28, 45, 62 and 361 
increased intraabdominal fat was observed in the imaging studies included in this review. The 362 
clinical importance of central obesity is its etiological link to cardiovascular disease.84 Long-363 
term conditions involving inflammatory pathophysiology have been associated with 364 
overweight and obesity. This is due to sustained activation of pro-inflammatory cytokines 365 
TNF-α and IL-6 over time leading to increased adipocytes.85 Moreover, recent findings have 366 
demonstrated a high prevalence of obesity in IBD in remission;6 however, further metabolic 367 
studies are required before conclusions can be drawn on whether FM accretion occurs in 368 
Crohn’s disease in remission.   369 
 370 
Need for Future Research  371 
Future studies should include a sample size calculation to ensure studies are adequately 372 
powered. Clearly defined Crohn’s disease activity groups, with a distinction between active 373 
disease and remission are also important. Furthermore, research quantifying nutrition status in 374 
active disease, remission and pre-surgical Crohn’s disease is needed to characterize nutrition 375 
deficits across the spectrum of Crohn’s disease to prioritize appropriate nutrition assessment 376 
provision in healthcare. There is insufficient evidence to determine if Crohn’s disease 377 
phenotype (inflammation location, presence of strictures or penetrating disease)86 has a 378 
definitive impact on nutrition status. With research priorities moving towards precision 379 
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medicine,87 future studies should investigate Crohn’s disease phenotype, and this may facilitate 380 
a personalized prediction of nutrition risk. 381 
 382 
Novel methods of measuring body composition via imaging should be explored. Abdominal 383 
CT and MRI scans can precisely locate specific deficits in muscle and FM and are routinely 384 
conducted in Crohn’s disease patients for clinical monitoring,88 but it is expensive to extend 385 
this method to HC.61 This limitation is highlighted by the authors of one study without a power 386 
calculation and a comparison of 24 MRI scans in Crohn’s disease patients with only 11 HC 387 
scans.26 Indeed there have been several recent publications reporting CT body composition in 388 
Crohn’s disease patients89-91 but none in comparison with a HC group. Further studies should 389 
explore readily available CTs and MRIs conducted in the clinical setting and assess their 390 
feasibility for use in body composition assessments.  391 
 392 
Once the evidence-base has comprehensively characterized nutrition deficits between active 393 
Crohn’s disease and remission, further research must explore how best to correct these deficits. 394 
For active Crohn’s disease patients this may involve lifestyle advice on increasing muscle 395 
strength with the use of nutritional supplements, thus reducing post-operative morbidity.92 In 396 
addition to the historical issue of muscle wasting in Crohn’s disease,83 attention is needed to 397 
better manage overweight and obesity in remission.6 Consequently, future research questions 398 
may address whether active Crohn’s disease patients require a different nutrition management 399 
approach from patients in remission. 400 
 401 
Conclusion 402 
Malnutrition is a significant issue in Crohn’s disease with deleterious consequences. However, 403 
as this narrative review demonstrates difficulties characterizing the type and prevalence of 404 
20 
 
nutrition deficits in this population exist due to the heterogeneous nature of Crohn’s disease. 405 
This review advocates that a nutrition assessment should include more than weight and BMI. 406 
As a result of the findings from this narrative review, an evidence-based comprehensive 407 
nutrition assessment tool for Crohn’s disease has been developed and will help guide clinician 408 
practice. 409 
 410 
Further research is required to elucidate the metabolic mechanisms for the deficits in nutrition 411 
status observed and how to correct them with medical and lifestyle management.  412 
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Figure 1: PRISMA flow diagram for studies included in the narrative review on nutrition 
assessment in Crohn’s disease.  
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Table 1. Assessment of body composition in patients with Crohn’s disease (CD) compared with an age and sex-matched healthy control group 
(HC). 
Author, 
Year, 
Country 
Participants (n) Disease 
activity 
Tech-
nique 
BMI a (kg/m2) 
mean (SDb) 
FMc (kg)  
mean (SDb) 
%FMd  
mean (SDb) 
FFMe (kg)  
mean (SDb) 
VATf (cm2 or 
mL) mean (SDb) 
 
 CD HC   CD HC CD HC CD HC CD HC CD HC 
Capristo et 
al. 199846 
Italy  
43 60 Remission BIAg 21.5* 23.7 12.2* 17.0 20.4*** 25.5  49.2 50.4   
Capristo et 
al. 199847 
Italy  
18 20 Remission BIAg  20.5* 23.6 12.6* 17.4 22.0* 26.4 45.6 49.5   
Mingrone et 
al. 199955 
Italy 
18 12 Mixed BIAg 21.6*  23.8  13.8***  19.0    48.0  47.7    
32 
 
Wiroth et 
al. 200513 
France 
41 
17Mh 
24Fi 
25 
10Mh 
15Fi 
Remission BIAg  
22.1 
22.1 
 
24.0 
21.4 
 
13.0 
15.3 
 
16.4 
16.0 
 
18.3 
25.8 
 
21.7 
27.5 
 
56.2 
42.9 
 
58.0 
41.0 
  
Filippi et al. 
200615 
France  
54 25 Remission BIAg 22.1 22.1 14.4* 16.6   49.2 46.7   
Valentini et 
al. 200816 
Austria, 
Germany & 
Italy 
 
94 
33Mh 
61Fi 
61 
20Mh 
41Fi 
Remission BIAg  
22.3 
22.1 
 
23.7 
21.8 
 
12.7 
18.1 
 
15.2 
16.6 
   
58.5**
* 
43.9 
 
67.4 
44.1 
  
Benjamin et 
al. 201145 
India 
80 100 Remission BIAg 21.6** 23.9  13.4  14.1 21.9  21.5 43.3** 48.9    
43   Active  18.8*  21.6 8.2*  14.1 15.7*  21.5 40.7*  48.9   
33 
 
Rizzi et al. 
201239 
Italy 
78 
42Mh 
36Fi 
75 
41Mh 
34Fi 
Mixed BIAg  
22  
21  
 
22  
22  
 
12** 
15* 
 
22  
21  
   
53 
37  
 
49  
40 
  
Lu et al. 
201644 
China 
 
 
150 
109
Mh 
41Fi 
256 
115Mh 
139Fi 
Mixed BIAg  
19.8***  
19.1***  
 
23.9 
22.1  
 
9.9***  
12.7***  
 
16.8 
17.2  
      
Katznelson 
et al. 200325 
USA 
20Mh 20Mh Mixed BIAg & 
CTj 
24.2  23.3    21.0*  17.7    115*** 69  
Buning et 
al. 201526 
Germany 
31Fi 19Fi Mixed MRIk 25.9 23.8       1185*  941 
Geerling et 
al. 199828 
32 
14Mh 
32 
14Mh 
Remission DEXAl 23.2 
22.8 
24.6 
26.4 
17.6 
13.2 
19.7 
18.4 
26.1 
18.4* 
28.7 
23.5 
48.6 
56.4 
49.7 
60.5 
  
34 
 
The Nether-
lands 
18Fi 18Fi 23.4 
 
23.3 20.9 20.7 32.1 32.7 42.6 41.2 
Tjellesen et 
al. 199834 
Denmark  
31 
13Mh 
18Fmi 
88 
19Mh 
69Fi 
Remission DEXAl  
23.5 
21.1 
 
23.9 
22.0 
 
20.3 
21.6 
 
19.2 
21.3 
 
27.8* 
38.8* 
 
23.1 
32.8 
 
51.8* 
34.9* 
 
62.2 
42.4 
  
Geerling et 
al. 199930 
The Nether-
lands 
20n 
40o 
20 
40 
Mixed 
Mixed 
DEXAl 22.7  
22.8 
23.0  
24.0  
19.4  
17.7  
19.5  
18.9 
28.3  
26.7  
29.2  
27.7  
49.2*  
47.1* 
46.8 
49.9 
  
Geerling et 
al. 200029 
The Nether-
lands 
23 23 Mixed DEXAl 22.2  22.7  18.5  19.0  27.5 28.7 48.9* 46.9   
Jahnsen et 
al. 200311 
Norway 
60 
24Mh 
36Fi 
60 
24Mh 
36Fi 
Mixed DEXAl 
 
 
23.3 
23.2* 
23.4 
23.4 
24.8 
22.5 
20.8 
16.7 
23.5 
20.0 
18.1 
21.3 
31.4 
23.1 
37.0 
29.2 
22.6 
33.6 
44.5* 
54.2**
* 
48.8 
61.0 
40.7 
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38.0** 
Cuoco et al. 
200848 
Italy  
13 20 Active DEXAl 19.8**  23.4  21.1 19.6   35.8**
*  
49.6    
Schneider et 
al. 200843 
France 
82 50 Remission DEXAl  21.1*  22.2 16.2 16.1 25.7  25.9  43.8 46.7   
a BMI body mass index, b SD standard deviation, c FM fat mass, d %FM percentage fat mass, e FFM fat free mass, f VAT visceral adipose tissue, g 
BIA bioelectrical impedance analysis, h M male, i F female, f CT computed tomography, k MRI magnetic resonance imaging, l DEXA dual 
energy X-ray absorptiometry, m weighted mean reported, n newly diagnosed, o longstanding disease > 5 years. 
CD versus HC * P<0.05, ** P<0.01, *** P<0.001. 
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Table 2. Blood markers of nutrition status in patients with Crohn’s disease (CD) compared with an age and sex-matched healthy control group 
(HC). 
Author, 
Year, 
Country 
Participants 
(n) 
Disease 
activity 
Folic acid 
(nmol/L) 
Mean (SDa) 
Vitamin B12 
(pmol/L) 
Mean (SDa) 
Vitamin C 
(µmol/L) 
Mean (SDa) 
Zinc (µmol/L) 
 
Mean (SDa) 
Copper 
(µmol/L) 
Mean (SDa) 
Selenium 
(µmol/L) 
Mean (SDa) 
 CD HC  CD HC CD HC CD HC CD HC CD HC CD HC 
Kallel et 
al.(2011)5
0 Tunisia  
 
89 103 Mixed 19.3 
(6.9) 
18.4 
(7.0) 
218**
* 
(118) 
279 
(125) 
        
Yakut et 
al. 
(2010)67 
Turkey  
 
45 53 Mixed 17.4 
(12.0) 
22.4 
(7.5) 
207 
(122) 
252 
(132) 
        
37 
 
Geerling 
et al. 
(1999)62 
The 
Nether-
lands 
 
20b 
32c 
20 
32 
Remission 
Mixed 
      12.4 
12.0* 
13.0 
13.1 
    
Geerling 
et al. 
(2000)29 
The 
Nether-
lands 
 
23b 23 Mixed 10.7 
(9.1) 
12.4 
(5.6) 
225* 
(60.7) 
270 
(88.2) 
47.6 
(17.7)  
54.5 
(22.9) 
12.3 
(3.0) 
12.9 
(1.3) 
23.6 
(8.9) 
22.2 
(7.4) 
0.92 
(0.16) 
0.99 
(0.16) 
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Geerling 
et al. 
(1998)28 
The 
Nether-
lands 
 
32 32 Remission 14.4 
(13.4) 
13.4 
(5.88) 
403 
(282) 
263 
(91.5) 
35.3**
* 
(25.8) 
57.8 
(22.3) 
12.0** 
(1.7) 
13.4 
(2.2) 
19.1 
(4.6) 
20.1 
(6.9) 
0.86**
* 
(0.14) 
1.30 
(0.15) 
Hinks et 
al. 
(1988)64 
UKd 
 
11 22 Active       12.7 
(1.8) 
12.9 
(1.7) 
17.3 
(3.3) 
16.3 
(2.6) 
  
Ringstad  
et al. 
(1993)65 
Norway  
47b 
27e 
20f 
123 
76e 
47f 
Not stated        
14.4 
13.5 
 
12.7 
12.9 
 
20.8**
* 
23.8† 
 
15.8 
18.1 
 
1.31**
* 
1.24† 
 
1.45 
1.37 
39 
 
 
Gentsche
w et al. 
(2012)63 
New 
Zealand  
 
351 853 Not stated           1.37**
* 
(0.01) 
1.41 
(0.01) 
Wendlan
d et al 
(2001)66 
Canada  
37 37 Mixed     64.0** 
(4.6) 
78.4 
(2.9) 
    0.81 
(0.04) 
0.80 
(0.04) 
a SD standard deviation, b newly diagnosed Crohn’s disease, c diagnosed Crohn’s disease for more than 5 years,d UK United Kingdom, e M male, 
f F female. 
CD versus HC * P<0.05, ** P<0.01, *** P<0.001 
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Table 3. Vitamin D concentration and prevalence of deficiency in patients with Crohn’s disease (CD)  compared with an age and sex-matched 
healthy control group (HC). 
Author, 
Year 
Country Participants 
(n)  
Disease 
activity 
Vitamin D nmol/L  
mean (SDa) 
Vitamin D 
25(OH)D3 ng/mL 
mean (SDa) 
Suboptimal 
micronutrient level 
n (%) 
Suboptimal 
criteria 
  CD  HC  CD HC CD HC CD HC  
Geerling et 
al. (1998)28 
The 
Nether-
lands 
32 32 Remission     18** 
(56.0) 
9  
(28.0) 
< 70 nmol/L 
(summer and 
autumn) or < 25 
nmol/L (winter) 
Ardizzone 
et al. 
(2000)68 
 
Italy 51 30 Mixed   19.5 
(7.5) 
18.1 
(7.9) 
   
Duggan et 
al. (2004)27 
Ireland 44 44 Remission 75.0* 
(28.7)  
105.3 
(55.5) 
  3≠  
(6.8) 
2  
(4.5) 
< 40 nmol/L 
41 
 
 
Tajika et al. 
(2004)51 
 
Japan 33 15 Mixed   15.2 
(6.5) 
16.9 
(5.2) 
9  
(27.3) 
1  
(6.7) 
< 10 ng/mL 
Gilman et 
al. (2006)31 
 
Ireland 47 47 Remission 71.6*** 
(33.0)  
113 
(69.2)  
  9*  
(19.1) 
2  
(4.3) 
< 40 nmol/L 
Joseph et al. 
(2009)49 
 
India 34 34 Mixed   16.3* 
(10.8) 
22.8 
(11.9) 
27* 
(79.0) 
17 
(50.0) 
< 20 ng/mL 
Suibhne et 
al. (2012)33 
 
Ireland 81 70 Mixed 47.8 
(27.3) 
51.9 
(24.5) 
  51 
(63.0) 
36 
(51.0) 
< 50 nmol/L 
Grunbaum 
et al. 
(2013)32 
Canada 34 48 Remission 71.1 
(31.1) 
68.3 
(26.2)  
  10≠ 
(29.4) 
11 
(22.9) 
< 50 nmol/L 
42 
 
 
Salacinski 
et al. 
(2013)57 
 
USA 19 19 Remission   32.0 
(9.1) 
35.3 
(11.1) 
2≠ 
(10.5) 
1  
(5.3) 
< 20 ng/mL 
Dumitrescu 
et al. 
(2014)69 
 
Romania 14 94 Mixed   23.0* 
(10.0) 
31.0 
(13.0) 
5≠ 
(36.0) 
19 
(20.0) 
< 20 ng/mL 
Tan et al. 
(2014)70 
China 107 122 Mixed   11.6* 
(5.0) 
12.9 
(4.4) 
   
a SD standard deviation, ≠ no statistical test reported comparing CD and HC. CD versus HC * P<0.05, ** P<0.01, *** P<0.001 
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Table 4. Characteristics and outcomes of studies which assessed dietary intake of patients with Crohn’s disease (CD) compared with an age and 
sex-matched healthy control group (HC).  
Study, 
Country 
Assessment 
method 
Participants 
(n) 
Disease 
activity 
Outcome measures Differences compared with HC 
Capristo et 
al. 199846, 
Italy 
7-day food 
record 
CD n=43 
HC n=60 
Remission Macronutrient intake CD consumed less energy and less %TEa from fat 
than HC. 
      
Geerling et 
al. 199828, 
The 
Netherlands 
 
FFQb CD n=32 
HC n=32 
Remission Macro- and 
micronutrient intake 
Macro- and micronutrient intake similar except 
fibre and phosphorus intake lower in CD. 
Geerling et 
al. 1999 62 
FFQb & diet 
history 
CD n=20c 
CD n=32d 
HC n=52 
Remission 
Mixed 
Macronutrient intake Newly diagnosed CD had higher total 
carbohydrate and mono and disaccharide intake 
44 
 
The 
Netherlands 
 
than controls. Those with longstanding CD dietary 
intake was similar to HC. 
Geerling et 
al. 200029, 
The 
Netherlands 
FFQb CD n=23c  
HC n=23 
Active n=4 
Remission 
n=19 
Macro- and 
micronutrient intake 
CD %TEa from CHOe higher, lower intake of 
alcohol and PUFAf than HC. Micronutrient intake 
not different. CD with active disease had 
higher %TEa from CHOe than CD in remission. 
 
Katznelson et 
al. 200325, 
USA 
5-day food 
record 
CD n=20 
(male only) 
HC n=20 
Mixed Macronutrient intake %TEa from protein lower in CD. 
   
   
Duggan et 
al.200427, 
Ireland 
 
FFQb CD n=44 
HC n=44 
Remission Calcium & vitamin D 
intake 
Dietary intake not different. 
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Lomer et al. 
200438, UK 
7-day food 
record 
CD n=91 
HC n=91 
Remission Macronutrient and 
iron, vitamin C intake 
Macronutrient intake similar. Lower intake of 
iron, non-haem iron, iron from breakfast cereals 
and vitamin C. Similar intake of iron from animal 
tissue. 
  
   
Filippi et al. 
200615, 
France 
 
 
3-day food 
record 
CD n=54 
HC n=25 
Remission Macro- and 
micronutrient intake, 
RDA 
Macronutrient intake not different, CD had lower 
intake of beta-carotene, vitamin C and female CD 
had lower intake of vitamins B1, B6 and Mgg 
compared with HC females. Significantly less CD 
met RDAh for Zni, Mgg, Vitamins C, B6, E, B1, 
B-carotene compared with HC. 
 
Guerreiro et 
al. 200740, 
Portugal 
FFQb CD n=87 
HC n=80 
Remission  
 
Macro- and 
micronutrient intake, 
food exclusion 
behaviours 
Lower energy (also lower BMIj) and fibre 
intake. %TEa from CHOe higher and from fat 
lower than HC. Lower calcium, vitamins C, D, E, 
K, PUFAf intakes in CD (not controlled for energy 
46 
 
intake). Fruit and vegetables exclusion associated 
with low vitamin C & E intakes. 
 
Valentini et 
al. 200816, 
Austria, 
Germany & 
Italy 
 
FFQb CD n=94 
HC n=61 
Remission Food group intake CD eat less fruit, vegetables, milk products, fish 
and alcoholic drinks than HC. Similar intake of 
meat, sweets, snacks, fast food, oils/fats. 
Benjamin et 
al. 201145, 
India 
24hr-food 
recall 
CD n=123 
HC n=100 
Active n=43 
Remission 
n=80 
Macronutrient intake Macronutrient intake of active and remission CD 
not different. CD energy and protein intake lower 
than in HC, higher %TEa from CHOe and less 
from fat. 
a %TE percentage of total energy, b FFQ food frequency questionnaire, c newly diagnosed Crohn’s disease, d longstanding Crohn’s disease > 5 
years, e CHO carbohydrate, f PUFA polyunsaturated fatty acids, g Mg magnesium, h RDA recommended daily allowance, i Zn zinc, j BMI body 
mass index  
 
